文献速递慢性肾脏病

果寡糖对CKD患者内皮功能影响的随机对照试验

Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

这项双盲随机对照试验纳入46例非糖尿病CKD患者,随机接受12 g/日果寡糖或安慰剂治疗3个月,评估内皮功能与动脉僵硬度。结果显示果寡糖组IL-6显著下降,但两组FMD和PWV无差异;在基线FMD≥2.2%的探索性亚组中,果寡糖组FMD保持稳定而安慰剂组下降。

要点

  • 果寡糖12 g/日治疗3个月可降低非糖尿病CKD患者循环IL-6水平
  • 整体人群未观察到果寡糖对FMD或PWV的显著影响
  • 基线内皮损伤较轻者(FMD≥2.2%)中果寡糖可能有助于维持内皮功能

核心结论

  • 益生元果寡糖可降低CKD患者循环IL-6水平,仅在内皮损伤较轻者中维持内皮功能,对动脉僵硬度无影响。

研究设计与样本

  • 双盲随机对照试验,46例非糖尿病非透析CKD患者随机接受12 g/日果寡糖或安慰剂(麦芽糊精)治疗3个月。

主要发现

  • 果寡糖组IL-6显著下降(3.4 ± 2.1 pg/mL vs 2.6 ± 1.4 pg/mL;P = 0.04)。
  • 果寡糖组PCS呈下降趋势(55.4 ± 38.1 mg/L vs 43.1 ± 32.4 mg/L,P = 0.07)。
  • 两组间FMD和PWV无差异。
  • 基线FMD≥2.2%亚组中,果寡糖组FMD保持稳定而安慰剂组下降(组效应P = 0.135;时间效应P = 0.012;交互P = 0.002)。

关键数值与推荐

  • 研究人群平均年龄57.6 ± 14.4岁,eGFR 21.3 ± 7.3 mL/min/1.73 m2。
  • 果寡糖剂量12 g/日,疗程3个月,对照为麦芽糊精。

临床怎么用

  • 对非糖尿病CKD患者,果寡糖可能有助于降低炎症标志物IL-6,但整体内皮功能获益不明确,需进一步验证。

局限性

  • 样本量较小(46例),FMD亚组分析为探索性,结论需更大规模试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microbiota-derived uremic toxins have been associated with inflammation that could corroborate with endothelial dysfunction (ED) and increase cardiovascular risk in patients with chronic kidney disease (CKD). This trial aimed to evaluate the effect of the prebiotic fructooligosaccharide (FOS) on endothelial function and arterial stiffness in nondialysis CKD patients. METHODS: In a double-blind controlled trial, 46 nondiabetic CKD patients were randomized to receive 12 g/day of FOS or placebo (maltodextrin) for 3 months. Total p-cresyl sulfate (PCS) and indoxyl sulfate by high-performance liquid chromatography, urinary trimethylamine N-oxide by mass spectrometry, C-reactive protein, interleukin-6 (IL-6), serum nitric oxide and stroma-derived factor-1 alfa were measured at baseline and at the end of follow-up; endothelial function was assessed through flow-mediated dilatation (FMD) and arterial stiffness by pulse wave velocity (PWV). RESULTS: The mean (± standard deviation) age of the study participants was 57.6 ± 14.4 years, with an estimated glomerular filtration rate of 21.3 ± 7.3 mL/min/1.73 m2. During the follow-up, regarding the inflammatory markers and uremic toxins, there was a significant decrease in IL-6 levels (3.4 ± 2.1 pg/mL versus 2.6 ± 1.4 pg/mL; P = 0.04) and a trend toward PCS reduction (55.4 ± 38.1 mg/L versus 43.1 ± 32.4 mg/L, P = 0.07) only in the prebiotic group. Comparing both groups, there was no difference in FMD and PWV. In an exploratory analysis, including a less severe ED group of patients (FMD ≥2.2% at baseline), FMD remained stable in the prebiotic group, while it decreased in the placebo group (group effect P = 0.135; time effect P = 0.012; interaction P = 0.002). CONCLUSIONS: The prebiotic FOS lowered circulating levels of IL-6 in CKD patients and preserved endothelial function only in those with less damaged endothelium. No effect of FOS in arterial stiffness was observed.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Armani RG, Carvalho AB, Ramos CI, et al. Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial. Nephrol Dial Transplant. 2021. PMID: 33411910. doi:10.1093/ndt/gfaa335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。